Frontiers
Browse
Table_3_Individualization of Hematopoietic Stem Cell Transplantation Using Alpha/Beta T-Cell Depletion.pdf (73.92 kB)

Table_3_Individualization of Hematopoietic Stem Cell Transplantation Using Alpha/Beta T-Cell Depletion.pdf

Download (73.92 kB)
dataset
posted on 2019-02-11, 04:26 authored by Emelie Rådestad, Mikael Sundin, Johan Törlén, Sarah Thunberg, Björn Önfelt, Per Ljungman, Emma Watz, Jonas Mattsson, Michael Uhlin

Allogeneic hematopoietic stem cell transplantation (HSCT) is associated with several potentially lethal complications. Higher levels of CD3+ T-cells in the graft have been associated with increased risk of graft-versus-host disease (GVHD), but also beneficial graft-versus-leukemia effect and reduced infections. To tackle post-transplant complications, donor lymphocyte infusions have been used but with an increased risk of GVHD. To reduce this risk, we performed depletion of αβ T-cells and treated 12 patients post-HSCT suffering from infections and/or poor immune reconstitution. The αβ T-cell depleted cell products were characterized by flow cytometry. The median log depletion of αβ T-cells was −4.3 and the median yield of γδ T-cells was 73.5%. The median CD34+ cell dose was 4.4 × 106/kg. All 12 patients were alive 3 months after infusion and after 1 year, two patients had died. No infusion-related side effects were reported and no severe acute GVHD (grade III-IV) developed in any patient post-infusion. Overall, 3 months after infusion 11 out of 12 patients had increased levels of platelets and/or granulocytes. In conclusion, we describe the use of αβ T-cell depleted products as stem cell boosters with encouraging results.

History